Swiss Neurodegeneration Biotech Companies

Switzerland, particularly the regions of Basel, Zurich, and Lausanne, has emerged as a major European biotechnology hub for neurodegenerative disease research and drug development. This page provides an overview of Swiss biotech companies focused on Alzheimer's disease, Parkinson's disease, ALS, and related conditions.

Overview

Switzerland, particularly the regions of Basel, Zurich, and Lausanne, has emerged as a major European biotechnology hub for neurodegenerative disease research and drug development. This page provides an overview of Swiss biotech companies focused on Alzheimer's disease, Parkinson's disease, ALS, and related conditions.

Overview

The Swiss biotech ecosystem benefits from:

• World-class academic institutions (EPFL, University of Zurich, University of Basel)
• Strong venture capital funding
• Favorable regulatory environment
• Presence of major pharmaceutical companies (Roche, Novartis) fostering partnerships

Company Profiles

AC Immune SA

Location: Lausanne, Switzerland Founded: 2003 Ticker: ACIU (NASDAQ) Website: [acimmune.com](https://www.acimmune.com)

AC Immune is a clinical-stage biopharmaceutical company focused on developing precision medicines for neurodegenerative diseases using its proprietary SupraAntigen and Morphomer technology platforms.

Pipeline

| Program | Indication | Mechanism | Stage | Partner |
|---------|------------|-----------|-------|---------|
| Semorinemab (ACI-35) | Alzheimer's disease | Anti-tau liposome vaccine | Phase 2 | Roche |
| ACI-35.164 | Alzheimer's disease | Phospho-tau vaccine | Phase 1b/2a | Proprietary |
| ACI-40 | Parkinson's disease | Alpha-synuclein vaccine | Phase 1 | Roche |
| ACI-89 | ALS | TDP-43 vaccine | Preclinical | Proprietary |

AC Immune's approach focuses on immunotherapy targeting misfolded proteins characteristic of neurodegenerative diseases. Their tau vaccine programs have shown promising results in clinical trials, and their partnership with Roche provides significant resources for clinical development[^1].

Asceneuron SA

Location: Lausanne, Switzerland Founded: 2016 Website: [asceneuron.com](https://www.asceneuron.com)

Asceneuron is focused on developing small molecule therapeutics targeting tau pathology in Alzheimer's disease and other tauopathies.

Pipeline

| Program | Mechanism | Indication | Stage |
|---------|-----------|------------|-------|
| ASN51 | Tau aggregation inhibitor | Alzheimer's disease | Phase 1/2 |

The company's lead program, ASN51, represents a differentiated approach to addressing tau pathology, which correlates strongly with cognitive decline in AD patients. Asceneuron's small molecule approach offers potential advantages over antibody-based therapies in terms of blood-brain barrier penetration[^2].

Neurimmune

Location: Zurich, Switzerland Founded: 2007 Website: [neurimmune.com](https://www.neurimmune.com)

Neurimmune is a Swiss biotech company specializing in developing antibody-based therapeutics for neurodegenerative diseases using its proprietary Reverse Translational Medicine (RTM) platform.

Technology Platform

Neurimmune's RTM platform identifies natural human antibodies from healthy elderly individuals with cognitive resilience, leveraging the body's natural defense mechanisms against protein aggregation diseases.

Pipeline

| Program | Indication | Mechanism | Stage | Partner |
|---------|------------|-----------|-------|---------|
| NI-202 (Aducanumab) | Alzheimer's disease | Anti-Aβ antibody | Approved | Biogen |
| NI-301 | Alzheimer's disease | Tau-targeting antibody | Phase 1 | — |
| NI-402 | Parkinson's disease | Anti-α-synuclein antibody | Preclinical | — |
| NI-501 | ALS | TDP-43 targeting | Discovery | — |

Neurimmune's most notable achievement is aducanumab ( Aduhelm), developed in partnership with Biogen and approved by the FDA for Alzheimer's disease treatment[^3].

Vandria SA

Location: Geneva, Switzerland Founded: 2018 Website: [vandria.com](https://www.vandria.com)

Vandria develops novel therapeutics targeting mitochondrial function and cellular energetics in age-related diseases, including Alzheimer's and Parkinson's disease.

Pipeline

| Program | Mechanism | Indication | Stage |
|---------|-----------|------------|-------|
| VNA-318 | Mitochondrial modulator | Alzheimer's disease | Phase 1 |
| VNA-100 | Mitochondrial modulator | Parkinson's disease | Preclinical |

The company's approach focuses on modulating mitochondrial quality control mechanisms—enhancing mitophagy, promoting mitochondrial biogenesis, and improving cellular energetics to protect neurons from degeneration[^4].

MindMaze

Location: Lausanne, Switzerland Founded: 2012 Website: [mindmaze.com](https://www.mindmaze.com)

MindMaze is a neurotechnology company developing digital therapeutics and brain-computer interfaces for neurorehabilitation.

Focus Areas

• Stroke rehabilitation
• Traumatic brain injury recovery
• Neurological condition management
• Virtual reality-based therapies

Research Collaboration Ecosystem

Academic Institutions

| Institution | Location | Focus Areas |
|-------------|----------|-------------|
| EPFL | Lausanne | Neuroscience, neuroengineering |
| University of Zurich | Zurich | Neurodegeneration, Alzheimer's research |
| University of Basel | Basel | Neuroscience, drug discovery |
| University of Geneva | Geneva | Mitochondrial biology |

Industry Partnerships

The Swiss biotech companies frequently collaborate with:

• Roche (Basel) — Major pharmaceutical partner
• Novartis (Basel) — Neuroscience research
• Biogen — Antibody partnerships
• Life Molecular Imaging — Tau PET tracer development

Investment Landscape

Swiss neurodegeneration biotech companies have attracted significant investment:

• AC Immune: Publicly traded on NASDAQ, market cap ~00M
• Neurimmune: Strategic partnerships with Biogen and Bristol Myers Squibb
• Vandria: Series funding from Swiss and international VCs
• Asceneuron: Series A and B funding from European investors

Clinical Trial Activity

Switzerland-based companies are actively conducting clinical trials:

• NCT04759365: Asceneuron ASN51 Phase 1 (completed)
• NCT06612599: Asceneuron ASN51 Phase 2
• Multiple AC Immune tau and alpha-synuclein vaccine trials
• Vandria VNA-318 Phase 1 trials

Future Outlook

The Swiss neurodegeneration biotech sector is positioned for continued growth:

References

[^1]: [AC Immune Corporate Website](https://www.acimmune.com)
[^2]: [Asceneuron ASN51 Clinical Trial - NCT04759365](https://clinicaltrials.gov/study/NCT04759365)
[^3]: [Neurimmune RTM Platform](https://www.neurimmune.com/platform)
[^4]: [Vandria SA - ALZFORUM Therapeutics](https://www.alzforum.org/therapeutics/vandria-sa)
[^5]: [MindMaze Corporate Website](https://www.mindmaze.com)

Cross-References

• [Alzheimer's Disease Pipeline Companies](/companies/ad-pipeline-companies)
• [Parkinson's Disease Pipeline Companies](/companies/pd-pipeline-companies)](/proteins/parkin)
• [AC Immune](/companies/ac-immune)
• [Asceneuron](/companies/asceneuron)
• [Neurimmune](/companies/neurimmune)](/companies/neurimmune)
• [Vandria](/companies/vandria)